You are here

Good EULAR Response In Patients With Early Rheumatoid Arthritis

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
G. Gennimatas General Hospital /Rheumatology Clinic
Athens, Attica, 11527 Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. signed and dated informed consent document

2. 18 years of age and older at the time of consent

3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010
Rheumatoid Arthritis Classification Criteria

4. Patients who have been prescribed for first time to receive treatment with MTX +
Etanercept prior to enrollment to this study, following routine clinical practice and
according to the approved SmPC,

5. Patients with DAS28 ≥ 3.2

6. Duration of disease symptoms ≥ 6 weeks and ≤2 years

7. Failure to respond to prior DMARDs including MTX monotherapy according to routine
clinical practice.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Contraindications according to the SmPC

2. History of or present anti-TNFa or other biologic therapy for the treatment of RA

3. Known significant concurrent medical disease according to investigator's opinion and
the current SmPC

NCT01558089
Pfizer
Completed
Good EULAR Response In Patients With Early Rheumatoid Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
NCT00413699
All Genders
18+
Years
Multiple Sites
Good EULAR Response In Patients With Early Rheumatoid Arthritis
Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece
This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece
All subjects enrolled should meet the usual prescribing criteria for Etanercept as per the local product information and should be entered into the study at the investigator's discretion
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
patients with rheumatoid arthritis who fulfill the inclusion/exclusion criteria
Rheumatoid Arthritis
  • Drug: etanercept
    according to SmPC and clinical practice
  • Drug: methotrexate
    according to SmPC and clinical practice
etanercept + methotrexate
Interventions:
  • Drug: etanercept
  • Drug: methotrexate
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
76
May 2015
May 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. signed and dated informed consent document
  2. 18 years of age and older at the time of consent
  3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria
  4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,
  5. Patients with DAS28 ? 3.2
  6. Duration of disease symptoms ? 6 weeks and ?2 years
  7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.

Exclusion Criteria:

  1. Contraindications according to the SmPC
  2. History of or present anti-TNFa or other biologic therapy for the treatment of RA
  3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT01558089
B1801138
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2016

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now